BioSpace News Archive

- On the heels of the successful launch of a Global Healthcare practice in New York, London-based insights consultancy Basis Research renews its growth in Los Angeles with the hire of former Ipsos exec Jennifer Rittner as a Managing Partner. Jennifer will help Basis continue to expand its US business, particularly on the West Coast.

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced a new Executive Leadership Team structure designed to streamline its organizational structure and support its long-term growth strategy.

Bayer announced today that the Food and Drug Administration (FDA) has approved the inclusion of new safety data on pregnancy in the prescribing information for Betaseron® (Interferon beta 1b, IFNß-1b), which is indicated for the treatment of relapsing remitting multiple sclerosis (RRMS).

Vernalis Research, a Ligand Company, announced the achievement of a £1 million success milestone in its drug discovery collaboration with Asahi Kasei Pharma (AKP).

Online, non-profit university presents Elizabeth Leal with $2,000 Award

Therapies for breast cancer, multiple myeloma, and HIV ranked the highest across audit of commercial performance, therapeutic value, and R&D complexity.

Recognitions include first-ever Scrip Award for Best Use of Real-World Evidence and “Best in Show” Fierce Innovation Award for partnership with Datavant, as FDA issues framework highlighting potential of RWE to industry

Concert Pharmaceuticals (NASDAQ: CNCE) today announced that it has initiated its Phase 1 clinical program for CTP-692, which is being developed as a novel adjunctive treatment for schizophrenia, a devastating, chronic illness with significant unmet need. CTP-692 is a deuterated form of D-serine, an endogenous co-agonist of the N-methyl-D-aspartate (NMDA) receptor, which has been demonstrated to be important to mood, memory, and cognition.

Bristol-Myers Squibb Company (NYSE: BMY), Eisai Co., Ltd. and its U.S.-based precision medicine research & development subsidiary H3 Biomedicine Inc. (Massachusetts, “H3”) today announced a multi-year research collaboration focused on evaluating whether novel therapeutics leveraging H3’s RNA splicing platform can provide a more powerful response against cancer.

Exicure, Inc. (OTCQB:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today top-line results from a Phase 1 clinical trial evaluating XCUR17 in patients with mild-to-moderate chronic plaque psoriasis. XCUR17 is an SNA drug targeted to mRNA encoding interleukin 17 receptor alpha, or IL-17RA. IL-17RA is a key protein that propagates inflammation.